Grant Number:	5R01DA047952-04 Interpret this number
Primary Investigator:	Havens, Jennifer
Organization:	University Of Kentucky
Project Title:	Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: the Kentucky Viral Hepatitis Treatment (Key Treat) Study
Fiscal Year:	2022

ABSTRACT The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase access to treatment for the hepatitis C virus (HCV) in a rural Appalachian community in the midst of the opioid/HCV syndemic. This study seeks to examine whether removing barriers associated with accessing direct-acting antivirals (DAAs) for the treatment of HCV (high out-of-pocket costs, insurance restrictions requiring a specialist, abstinence, and significant liver damage) will significantly reduce the burden of HCV in Perry County, Kentucky. The proposed study is made possible by a significant drug donation from Gilead Sciences for sofosbuvir/velpatasvir, a 12-week, once per day, pan-genotypic DAA. KeY Treat proposes a multi-pronged approach to treating HCV using a mid-level provider model. In addition to DAA treatment, participants will be offered access to subsidized medication-assisted treatment, syringe services, and case management. We will leverage existing resources in the target community (public health, jail, hospital), as well as ongoing projects dedicated to increasing access to HCV care in affected communities (ECHO, FOCUS) to answer whether removing the major barriers to HCV treatment affect access, and what barriers remain. All RNA-positive residents of Perry County, Kentucky will be eligible/recruited for study participation (N≈900), and the following specific aims will be addressed: 1) determination of HCV treatment uptake among rural residents with chronic HCV; 2) examination of the predictors of treatment completion among those enrolled in KeY Treat; 3) examination of the characteristics of participants achieving sustained virologic response (SVR, or cure); 4) establishment of long-term re-infection rates among those achieving SVR; 5) examination of 5-year reductions in incidence and prevalence of HCV in the intervention community compared with a control county in rural Kentucky; and 6) evaluate the impact and cost-effectiveness of KeY Treat using mathematical modeling. The proposed research has tremendous potential to impact public health in the rural United States. The majority of counties identified in CDC’s recent HCV/HIV hotspot analysis were rural, and there is a real need to improve access to DAAs in order to prevent further HCV transmission, reduce the burden of advanced liver disease, and hepatocellular carcinoma in generations to come. Data from KeY Treat will inform policies around Medicaid/insurance restrictions for DAAs, and will deliver a much needed blueprint for the provision of HCV treatment in resource-deprived rural areas.




Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community.
Authors: Havens J.R. , Lofwall M.R. , Young A.M. , Staton M. , Schaninger T. , Fraser H. , Vickerman P. , Walsh S.L. .
Source: Journal Of Viral Hepatitis, 2024 Jun; 31(6), p. 293-299.
EPub date: 2024-03-04 00:00:00.0.
PMID: 38436098
Related Citations

Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis.
Authors: Artenie A. , Stone J. , Fraser H. , Stewart D. , Arum C. , Lim A.G. , McNaughton A.L. , Trickey A. , Ward Z. , Abramovitz D. , et al. .
Source: The Lancet. Gastroenterology & Hepatology, 2023 Jun; 8(6), p. 533-552.
EPub date: 2023-03-27 00:00:00.0.
PMID: 36996853
Related Citations

Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO.
Authors: Artenie A. , Luhmann N. , Lim A.G. , Fraser H. , Ward Z. , Stone J. , MacGregor L. , Walker J.G. , Trickey A. , Marquez L.K. , et al. .
Source: The Lancet. Gastroenterology & Hepatology, 2022 04; 7(4), p. 353-366.
EPub date: 2022-02-03 00:00:00.0.
PMID: 35122713
Related Citations

An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis.
Authors: Mafirakureva N. , Stone J. , Fraser H. , Nzomukunda Y. , Maina A. , Thiong'o A.W. , Kizito K.W. , Mucara E.W.K. , González Diaz C.I. , Musyoki H. , et al. .
Source: Addiction (abingdon, England), 2022 Feb; 117(2), p. 411-424.
EPub date: 2021-07-28 00:00:00.0.
PMID: 34184794
Related Citations

Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis.
Authors: Ward Z. , Stone J. , Bishop C. , Ivakin V. , Eritsyan K. , Deryabina A. , Low A. , Cepeda J. , Kelly S.L. , Heimer R. , et al. .
Source: The Lancet. Hiv, 2022 Jan; 9(1), p. e42-e53.
EPub date: 2021-12-09 00:00:00.0.
PMID: 34895484
Related Citations

Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
Authors: Ward Z. , Mafirakureva N. , Stone J. , Keevans M. , Betts-Symonds G. , Crowley D. , McHugh T. , Avramovic G. , Lambert J.S. , Vickerman P. .
Source: The International Journal On Drug Policy, 2021 10; 96, p. 103394.
EPub date: 2021-08-17 00:00:00.0.
PMID: 34412938
Related Citations

Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C.
Authors: Havens J.R. , Schaninger T. , Fraser H. , Lofwall M. , Staton M. , Young A.M. , Hoven A. , Walsh S.L. , Vickerman P. .
Source: Bmj Open, 2021-07-05 00:00:00.0; 11(7), p. e041490.
EPub date: 2021-07-05 00:00:00.0.
PMID: 34226208
Related Citations

Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
Authors: Hajarizadeh B. , Grebely J. , Byrne M. , Marks P. , Amin J. , McManus H. , Butler T. , Cunningham E.B. , Vickerman P. , Martin N.K. , et al. .
Source: The Lancet. Gastroenterology & Hepatology, 2021 07; 6(7), p. 533-546.
EPub date: 2021-05-07 00:00:00.0.
PMID: 33965006
Related Citations

Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.
Authors: Arum C. , Fraser H. , Artenie A.A. , Bivegete S. , Trickey A. , Alary M. , Astemborski J. , Iversen J. , Lim A.G. , MacGregor L. , et al. .
Source: The Lancet. Public Health, 2021 05; 6(5), p. e309-e323.
EPub date: 2021-03-26 00:00:00.0.
PMID: 33780656
Related Citations

Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis.
Authors: Stone J. , Degenhardt L. , Grebely J. , Larney S. , Altice F.L. , Smyrnov P. , Rahimi-Movaghar A. , Alavi M. , Young A.M. , Havens J.R. , et al. .
Source: The Lancet. Psychiatry, 2021 04; 8(4), p. 301-309.
EPub date: 2021-02-25 00:00:00.0.
PMID: 33640039
Related Citations